Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2 Pipeline Review, H2 2018
Summary
Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2 pipeline Target constitutes close to 10 molecules. The latest report Prostaglandin D2 Receptor 2 Pipeline Review, H2 2018, outlays comprehensive information on the Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2 Prostaglandin D2 PGD2 receptors are G proteincoupled receptors that binds and is activated by prostaglandin D2. It mediates the proinflammatory chemotaxis of eosinophils, basophils, and Th2 lymphocytes generated during allergic inflammation. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 1, 2 and 1 respectively. Report covers products from therapy areas Respiratory, Dermatology, Immunology, Central Nervous System, Ear Nose Throat Disorders and Ophthalmology which include indications Asthma, Androgenic Alopecia, Chronic Obstructive Pulmonary Disease COPD, Allergic Asthma, Allergic Rhinitis, Allergic RhinoConjunctivitis, Allergies, Inflammation and Nasal Polyps Nasal Polyposis.
Furthermore, this report also reviews key players involved in Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2
The report reviews Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2 targeted therapeutics and enlists all their major and minor projects
The report assesses Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Prostaglandin D2 Receptor 2 Chemoattractant Receptor Homologous Molecule Expressed On Th2 Cells or G Protein Coupled Receptor 44 or GPR44 or CD294 or PTGDR2 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope